The use of flow cytometry has been critical in establishing methods to isolate and characterize hematopoietic stem cells (HSCs) and their progenitors. For more than 30 years, researchers have been uncovering novel markers that when used in combination significantly enhance the purification of HSCs from murine and human bone marrow. The complex interface between HSCs, the lymphohematopoietic system, and their niches, has made identification of HSC markers critical to understanding their biological nature, more so than other adult stem cell populations. Here we review the phenotypic markers and strategies used to purify HSCs, the appropriateness of using these markers for comparisons of HSC function at different stages of ontogeny, and their utility in defining the lineage bias in the HSC compartment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-62703-317-6_1 | DOI Listing |
Allogeneic haematopoietic stem cell transplantation (alloHSCT) is safe and effective for adolescents and adults with inborn errors of immunity (IEI) with severe disease manifestations of their disease. The haematopoietic cell transplantation comorbidity index (HCT-CI) score predicts transplant survival in non-malignant diseases, including IEIs. We hypothesised that immune dysregulation pre-transplant may also influence transplant outcomes.
View Article and Find Full Text PDFRev Med Chil
June 2024
Servicio de Medicina física y Rehabilitación, Hospital del Salvador, Santiago, Chile.
Autologous Stem-Cell Transplantation (ASTC) has proven efficacy in several hematological malignancies. The greatest antineoplastic effect achieved with intensified chemotherapy is associated with severe myelotoxicity. The infusion of autologous hematopoietic precursors and transfusion support during the period of aplasia reduces the time and depth of cytopenias, decreasing the risk of bleeding, anemia and life-threatening infections.
View Article and Find Full Text PDFCancer
January 2025
Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Background: Patients with lysine methyltransferase 2a (KMT2A)-rearranged (KMT2A-r) acute myeloid leukemia (AML) are assigned to intermediate-risk and adverse-risk categories at diagnosis. However, the value of molecular measurable residual disease (MRD) status in patients who have KMT2A-r AML before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult cohorts has rarely been evaluated.
Methods: Patients with KMT2A-r AML who achieved complete remission and subsequently underwent allo-HSCT between January 2015 and January 2023 were included in this analysis.
Expert Rev Clin Immunol
January 2025
Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients are severely immunocompromised and susceptible to bacterial, viral, and fungal infections. Despite improved anti-microbial prophylaxis and preemptive strategies, bacterial bloodstream infections (BSIs) occur frequently in allo-HSCT recipients and are associated with increased morbidity and mortality. Cytomegalovirus (CMV) and Epstein Barr virus (EBV) are the most relevant viruses following allo-HSCT and remain major concerns.
View Article and Find Full Text PDFHealth Serv Insights
January 2025
Department of Health Care Sciences, Marie Cederschiöld University, Stockholm, Sweden.
Introduction: Allogeneic stem cell transplantation (allo-HCT) involves a long trajectory with high risk of complications. In person-centred care (PCC), patients' needs, resources and the care relationship are central to the care process. Healthcare professionals' (HCPs) ratings of PCC have not previously been investigated in this context.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!